New hope to stop aggressive breast Cancer's return
NCT ID NCT07407517
Summary
This study is testing whether adding a pill called everolimus after standard chemotherapy helps prevent cancer from coming back in people with early-stage triple-negative breast cancer. About 900 patients who've had surgery and chemotherapy will be randomly assigned to receive either standard care alone or standard care plus everolimus for one year. The main goal is to see if the extra treatment helps more patients stay cancer-free for at least three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.